Manuela Doroana

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 322 citations · Full text

Cell-Associated Viral Burden Provides Evidence of Ongoing Viral Replication in Aviremic HIV-2-Infected Patients

Rui S. Soares, Rita Tendeiro, Russell B. Foxall et al. · Journal of Virology · 2010 · 51 citations · Full text

Aviremic Hiv-2-infected Patients, Plasma Viremia, Viral Replication +18

Kinetics of the Changes of Lymphocyte Subsets Defined by Cytokine Production at Single Cell Level During Highly Active Antiretroviral Therapy for HIV-1 Infection

Ana E. Sousa, Ana F. Chaves, Manuela Doroana et al. · The Journal of Immunology · 1999 · 48 citations · Full text

Baseline Susceptibility of Primary HIV-2 to Entry Inhibitors

Pedro Borrego, Rita Calado, José Maria Marcelino et al. · Antiviral Therapy · 2011 · 47 citations

Change in Vitamin D Levels and Risk of Severe Vitamin D Deficiency over 48 Weeks among HIV-1-Infected, Treatment-Naive Adults Receiving Rilpivirine or Efavirenz in a Phase III Trial (Echo)

David A. Wohl, Chloe Orkin, Manuela Doroana et al. · Antiviral Therapy · 2013 · 40 citations